Can a skin ointment calm two stubborn redness conditions?

NCT ID NCT06013371

Terminated Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This phase 2 trial tests whether a once-daily topical ointment called PF-07038124 can ease moderate-to-severe seborrheic dermatitis and papulopustular rosacea. Adults with either condition will apply the ointment or a placebo for 8 weeks, with follow-up visits to check skin improvements and safety. The goal is to see if blocking PDE4 in the skin reduces redness, scaling, and inflammatory bumps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PF-07038124, a topical ointment that blocks PDE4 to reduce skin inflammation
What this could lead to: If successful, this could offer a new non-steroid topical treatment option for two common, chronic skin conditions that cause redness, scaling, and bumps.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not hold up in larger studies. The ointment may cause skin irritation or other side effects, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAPULOPUSTULAR ROSACEA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rosacea seborrheic dermatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAPULOPUSTULAR ROSACEA SEBORRHEIC DERMATITIS

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.